linjc16/ctgov huggingface dataset:
Autoantibodies on Spinal Cord Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the autoantibody profiles after spinal cord injury and their role in spontaneous functional recovery.

Detailed Description
-----------------
Most patients experience variable degrees of functional recovery after spinal cord injury (SCI), predominantly in the first months after lesion. In SCI animal models, autoantibodies are pathogenic and their titers rise up at the time when spontaneous recovery stops. The aim of this study is to determine the autoantibody profiles after SCI and to infer their relation with functional recovery. To achieve this, autoantibody profiles, biochemical, hematological and immune-related parameters (cytokines, chemokines and growth factors) will be determined from a serum blood sample and functional recovery will be evaluated accordingly to standardized scales.

Official Title
-----------------
Role of Autoantibodies in Spontaneous Functional Recovery After Spinal Cord Injury

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Other: Blood collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Traumatic or non-progressive vascular SCI Less than 45 days after lesion Any neurological level Complete and incomplete lesions If patient has been treated with glucocorticoids, it should have passed at least 7 days from the end of the treatment Exclusion Criteria: Cauda equina syndrome Autoimmune disorder Tumor (even if benign) Neurodegenerative disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spinal cord injury<br>Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later. | Other: Blood collection<br>* Blood collection from the subject's arm<br>|
| Controls<br>Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once. | Other: Blood collection<br>* Blood collection from the subject's arm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in ASIA scores |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in neurological level of injury |  | 4 months | 
| Change in ASIA impairment scale (AIS) |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
autoantibodies
Development of a Methodology to Design a High Order Sliding Mode Controller for Drug Dosage

Study Overview
=================
Brief Summary
-----------------
The aim of this observational study is to create a data base to extract feature of fast-acting drugs that can be monitor in real time to design control strategies based on high order sliding mode controller to create a robust drug infusion system.

Detailed Description
-----------------
The aim of this observational study is to create a database to extract feature of fast-acting drugs that can be monitor in real time to design control strategies based on high order sliding mode controller to create a robust drug infusion system. The observed drugs in this study are fast acting insulin, propofol and sodium nitroprusside. The effect of insulin will be measured by a continuous glucose monitor, the effect of propofol by a bispectral index monitor and the the effect of sodium nitroprusside by a invasive blood pressure monitor.

Official Title
-----------------
Development of a Methodology to Design a High Order Sliding Mode Controller for Drug Dosage

Conditions
-----------------
Diabetes, Hypertension, Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status I, II, II Exclusion Criteria: Impossibility to measure depth of anesthesia or invasive blood pressure. Impossibility of using glucose monitor.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glucose monitoring<br>Glucose will be monitor in patients using fast-acting insulin. | |
| Depth of anesthesia monitoring<br>Depth of anesthesia will be monitor in patients undergoing cardiac surgery. | |
| Blood pressure monitoring<br>Invasive blood pressure will be monitor in patients undergoing cardiac surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose | The glucose will be measured by a continuous glucose monitor. For the group of patients for diabetes. Note: This protocol has three primary outputs because its objective is to create a database of each output to analyze the response to the associated drug (insulin, propofol and sodium nitroprusside. | Every 5 minutes during 3 days. | 
| Bispectral Index | Depth of anesthesia will be measured by a Bispectral Index monitor. | Every second during surgery | 
| Invasive blood pressure |  | Every 5 minutes during surgery |
The Effect of Intravenous (IV) Patient Controlled Analgesic (PCA) With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy

Study Overview
=================
Brief Summary
-----------------
The effect of IV PCA with ketorolac or fentanyl combined with caudal block for postoperative analgesia in small children undergoing intravesical ureteroneocystostomy.

Official Title
-----------------
The Effect of IV PCA With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy

Conditions
-----------------
Ureteroneocystostomy

Intervention / Treatment
-----------------
* Drug: ketorolac, fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients scheduled for elective ureteroneocystostomy were enrolled. Exclusion Criteria: History of allergy to aspirin or NSAIDs Peptic ulcer disease, and renal function impairment. And local infection foci on back, spinal anomalies Infectious diseases Neurologic disorders Seizures and coagulopathies were excluded for sacral epidural block.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ketorolac<br> | Drug: ketorolac, fentanyl<br>* intravenous PCA<br>|
| Experimental: fentanyl<br> | Drug: ketorolac, fentanyl<br>* intravenous PCA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Children's Hospital of Eastern Ontario Pain Scale, CHEOPS and Faces, Legs, Activity, Cry, and Consolability, FLACC |  | postoperative 24 hours, 48hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric patients (6 months-5 years) scheduled elective ureteroneocystostomy
Hospitalary Chronic Obstructive Pulmonary Disease Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to create an institutional registry of Chronic Obstructive Pulmonary disease through a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.

Detailed Description
-----------------
The main goal is to describe the characteristics of chronic obstructive pulmonary disease patients, including their clinical, spirometric, exacerbation and mortality characteristics within the population of the Hospital Italiano de Buenos Aires.

Official Title
-----------------
Hospitalary Chronic Obstructive Pulmonary Disease Registry

Conditions
-----------------
COPD Exacerbations, Death

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 40 years with a chronic obstructive pulmonary disease diagnosis according to global obstructive lung Global initiative for chronic Obstructive Lung Disease criteria. Follow up at the Hospital Italiano de Buenos Aires. Exclusion Criteria: Refusal to participate or to agree to the informed consent. Known non chronic obstructive pulmonary disease respiratory disease (ej: Lung Cancer, Tuberculosis, Pulmonary Fibrosis, Neumoconiosis, Cystic Fibrosis, Sarcoidosis, etc) Severe alpha-1 antitripsin deficit (typr SZ or ZZ) Previously thoracic surgery (ej: lung volume reduction, lung transplantation).

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | All cause of death | At 6 months after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity | Saint George respiratory questionnaire | At 6 months after enrollment | 
| Functional decline (Forced expired volume at one second) | Forced expired volume at one second | At 12 months after enrollment | 
| Exacerbations (defined as an increase in symptoms that requires treatment) | Number of exacerbations in the timeframe (defined as an increase in symptoms that requires treatment) | At 12 months after enrollment |
Treatment of Head Lice Infestation Using Novel Ultrasonic Comb

Study Overview
=================
Brief Summary
-----------------
A pilot study to evaluate safety and efficacy of the Lucy combined with LucyGel in killing head lice and their eggs. 23 participants will be enrolled in this study. The first 12 will be combed with model A and the remaining 11 will be combed with model B

Conditions
-----------------
Pediculus Capitis

Intervention / Treatment
-----------------
* Device: The Lucy ultrasonic comb models A and B combined with the LucyGel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and Females Age 6 years and older at the time of enrollment Must have an active head lice infestation of at least 10live head lice (found within 5 minutes of mechanic search). Hair must be at least 3 cm long. Written informed consent - by patient (if over 18 years of age), or by a parent (if patient is under 18 years of age). For females of childbearing potential, a statement declaring that she is not currently pregnant. Exclusion Criteria: Used any chemical head lice treatment in the 7 days preceding the trial treatment Used antibiotics in the week preceding treatment Open wounds in the treatment area Skin irritation in the treatment area Individuals with skin/scalp condition at the treatment site which, in the opinion of the investigator, will interfere with treatment or evaluation Known allergies to any of the gel's components Participant that is already enrolled in another study Participant who can't be combed with fine Comb dense ASSY2000

Ages Eligible for Study
-----------------
Minimum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment<br> | Device: The Lucy ultrasonic comb models A and B combined with the LucyGel<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events of the device and treatment | measured by AE | up to three days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality of up to 70% of the mature head lice 3 hours post treatment |  | 3 hours post treatment | 
| Mortality of up to 50% of the head lice eggs 14 days post treatment. |  | 14 days post treatment |
Impact of Race/Ethnicity on Platelet Function

Study Overview
=================
Brief Summary
-----------------
The effects of race/ethnicity on platelet function and response to antiplatelet agents will be assessed using healthy participants and coronary heart disease patients from at least 5 racial/ethnic groups.

Detailed Description
-----------------
The effects of race/ethnicity on platelet function and response to antiplatelet agents will be assessed using 125 healthy subjects, 250 coronary heart disease patients treated with aspirin, and 250 coronary heart disease patients treated with aspirin and a P2Y12 receptor antagonist, clopidogrel or prasugrel. A minimum of 25 healthy people, 50 people taking only aspirin, and 50 people taking aspirin and clopidogrel/prasugrel will be recruited for at least 5 racial/ethnic groups.

Official Title
-----------------
Impact of Race/Ethnicity on Platelet Function

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Each subject must fulfill the following criteria in order to be included in the study. The subject must be capable of understanding the nature of the study and executing an informed consent document. The subject must be aged 19 years or older. For healthy subjects, the subject must deny taking any medications that affect platelet function for at least 7 days before blood collection. For diseased patients, subjects with documented CAD are eligible to participate if they have been treated with antiplatelet therapy of aspirin (81 to 325 mg/day) with and without clopidogrel (75 mg/day) or another P2Y12 antagonist for at least one month. Exclusion Criteria: For healthy volunteers, subjects who fulfill one or more of the following criteria will be excluded from the study. taking medications for chronic cardiovascular diseases. illnesses requiring hospitalization or surgery within the last three months. history of drug or alcohol abuse. history of recent anemia or thrombocytopenia. history of excessive bleeding or thrombosis. pregnancy. For coronary heart disease subjects, subjects who fulfill one or more of the following criteria will be excluded from the study. illnesses requiring hospitalization or surgery within the last one month. history of drug or alcohol abuse. history of recent anemia or thrombocytopenia. pregnancy. recent bleeding diathesis malignancy renal insufficiency liver dysfunction treatment with warfarin or glycoprotein (GP) IIb/IIIa antagonists during the preceding 14 days

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet reactivity | Platelet reactivity as measured by platelet function tests | baseline only |
Northern Colorado COVID-19 Biobank

Study Overview
=================
Brief Summary
-----------------
The NoCo-CoBio Project is a biobanking effort to store and preserve saliva, nasopharyngeal, stool and blood specimens from SARS-CoV-2 PCR (polymerase chain reaction) positive individuals.

Detailed Description
-----------------
The investigators have created a biorepository of stool, saliva, nasopharyngeal swab specimens, peripheral blood mononuclear cells, serum, and plasma from SARS-CoV-2 infected individuals for research purposes. The multifaceted biorepository will be used to establish markers predicting various presentations of COVID-19 (coronavirus disease 2019).

Official Title
-----------------
Northern Colorado Coronavirus Biobank: A Biorepository for Acute and Convalescent Patient Samples From Coloradoans Infected With SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2)

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those who have had a positive SARS-CoV-2 PCR test Exclusion Criteria: under 18 years of age pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute phase of SARS-CoV-2 infection<br>Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study. | |
| Convalescent phase of SARS-CoV-2 infection<br>Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease | Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of markers and predictors of post acute sequelae of COVID-19 | Evaluation of markers and predictors of post acute sequelae of COVID-19 | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biobank, biorepository, SARS-CoV-2 infection, COVID-19, coronavirus
Airway Management for Trigeminal Thermal Coagulation

Study Overview
=================
Brief Summary
-----------------
Airway management of patients undergoing thermal coagulation of the Gasserian ganglion is very delicate. This is because of the specific operation site and moreover patients should recover quickly from anesthesia to follow verbal intraoperative commands of the surgeon. Endotracheal intubation or laryngeal mask of course hinders the patient from speaking. An obvious alternative airway management, as performed in this preliminary study, is a nasopharyngeal placed tube. The purpose of the present study is to objectify the gas exchange in patients during this new ventilation technique.

Official Title
-----------------
Airway Management in Patients Undergoing Thermal Ganglion Gasseri Coagulation, a New Method - Preliminary Results

Conditions
-----------------
Airway Management

Intervention / Treatment
-----------------
* Other: Nasopharyngeal Tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients undergoing thermal coagulation of the Gasserian ganglion Exclusion Criteria: Body weight over 100 kg Recurrent nasal bleeding Patients suffering from reflux disease Additional risk of aspiration (e.g. hernia diaphragmalis)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Nasopharyngeal Tube<br>Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention. | Other: Nasopharyngeal Tube<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood gas exchange | Blood gas analyses will be determined at three time points perioperatively. The first measurement, at base line, will be performed preoperatively, the second one after puncture of the Gasserian ganglion and the third during the thermal coagulation of the Gasserian ganglion. | Before and during the neurosurgical intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SpO2 oxygen saturation (pulse oximeter) |  | Before and during the neurosurgical intervention | 
| Hemodynamic parameters |  | Before and during the neurosurgical intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nasopharyngeal tube, airway management, thermal coagulation of the Gasserian ganglion
Study of ONO-1101 in Patients Scheduled for Coronary Angiography

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

Official Title
-----------------
Study of ONO-1101 in Patients Scheduled for Coronary Angiography, a Double-Blind, Randomized,Placebo-Controlled, Parallel Group, Multi-Center Study

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: ONO-1101
* Drug: ONO-1101
* Drug: ONO-1101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 years of age or older Heart rate less than 90 beats/min and more than 70 beats/min at entering the CT room Exclusion Criteria: Previous allergic reactions to contrast agent Renal failure Asthma Concomitant beta-receptor blocking agent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: P<br> | Drug: ONO-1101<br>* placebo for 1 minute IV<br>|
| Experimental: E2<br> | Drug: ONO-1101<br>* 0.125 mg/kg for 1 minute IV<br>|
| Experimental: E1<br> | Drug: ONO-1101<br>* 0.06 mg/kg for 1 minute IV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CT image quality |  | one day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate |  | For less than one month | 
| CT diagnostic accuracy |  | For less than one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ONO-1101, Coronary Artery Disease, Multi-slice CT